Optimal genome profiling for re-biopsy of TKI resistant tumour

Date 08 October 2016
Event ESMO 2016 Congress
Session Definition and management of oligoprogression during treatment with TKI inhibitors
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Presenter Keith Kerr
Authors K. Kerr
  • Aberdeen Royal Infirmary, AB25 2ZN - Aberdeen/GB